NextCure, Inc. (NXTC): CMO Dr. Udayan Guha, M.D., Ph.D. terminated without cause

Events in this filing

Item 5.02 as filed

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
​
On October 26, 2026 NextCure, Inc. (the “Company”) determined that the employment of Dr. Udayan Guha, M.D., Ph.D., Chief Medical Officer and a named executive officer of the Company, will be terminated effective October 31, 2026, in contemplation of the pending merger of the Company and Avere Therapeutics, Inc (the “Merger”).
​
In connection with his departure, Dr. Guha entered into a severance agreement and release with the Company (the “Severance Agreement”). In exchange for a release of claims in favor of the Company, the Severance Agreement provides for severance benefits consistent with those provided for a termination without cause under Dr. Guha’s existing employment agreement, as described in the Company’s Definitive Proxy Statement, filed with the Securities and Exchange Commission on April 24, 2026 (the “Employment Agreement”). Subject to and conditioned upon the occurrence of the closing of the Merger, the Severance Agreement provides for additional severance equal to the enhanced severance benefits for a termination without cause in relation to a change in control, as set forth in Dr. Guha’s Employment Agreement.
​
The Company and its Board of Directors thank Dr. Guha for his leadership at the Company and are grateful for his many valuable contributions during his tenure.
​
​
​